تحميل...

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer

BACKGROUND: Carboplatin remains a first-line agent in the management of epithelial ovarian cancer (EOC). Unfortunately, platinum-resistant disease ultimately occurs in most patients. Using a novel EOC cell line with acquired resistance to carboplatin: PEO1CarbR, genome-wide micro-array profiling ide...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Coley, H M, Safuwan, N A M, Chivers, P, Papacharalbous, E, Giannopoulos, T, Butler-Manuel, S, Madhuri, K, Lovell, D P, Crook, T
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Publishing Group 2012
الموضوعات:	Translational Therapeutics
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3273354/ https://ncbi.nlm.nih.gov/pubmed/22233925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.566
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer

مواد مشابهة